F. Rolland

G. Pignot, M. Rouprêt, É. Lechevallier, 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.

A. Ravaud, B. Escudier, S. Oudard, 2013, Clinical genitourinary cancer.

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

B. Duclos, S. Oudard, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

A. Ravaud, J. Machiels, G. Deplanque, 2015, European urology.

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

D. Cella, R. Bukowski, C. Szczylik, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.

G. Gravis, S. Ladoire, D. Pouessel, 2022, European journal of cancer.

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.

K. Harrington, É. Remenár, M. Forster, 2019, European journal of cancer.

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

S. Culine, C. Logothetis, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC).

R. Bukowski, B. Schwartz, C. Szczylik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

S. Culine, Y. Allory, W. Hilgers, 2021, Clinical genitourinary cancer.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

S. Culine, Y. Allory, G. Gravis, 2021, Clinical genitourinary cancer.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

S. Culine, S. Chevret, G. Deplanque, 2016, European journal of cancer.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

S. Culine, C. Logothetis, G. Le Teuff, 2017, European journal of cancer.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

S. Culine, G. Gravis, N. Houédé, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases.

G. Calais, E. Baudin, E. Babin, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma

K. Bensalah, J. Patard, A. Ravaud, 2018, The New England journal of medicine.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004–02

J. Bourhis, N. Daly-Schveitzer, Y. Tao, 2013, Radiation oncology.

Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study.

G. Calais, C. Sire, P. Garaud, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study.

G. Calais, C. Sire, D. de Raucourt, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group.

B. Duclos, B. Escudier, S. Oudard, 2010 .

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

J. Bourhis, E. Babin, C. Borel, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).

C. Sire, P. Fournel, Y. Tao, 2022, European journal of cancer.

Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).

J. Bourhis, J. Thariat, C. Sire, 2020, European journal of cancer.

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.

A. Ravaud, S. Oudard, B. Escudier, 2014, Clinical genitourinary cancer.

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

David Pérol, Sylvie Négrier, J. Bay, 2011, The Lancet. Oncology.

Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy {+/-} docetaxel--An analysis of final safety results.

S. Culine, S. Oudard, P. Beuzeboc, 2010 .

Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinib

J. Patard, D. Lambrechts, J. Zucman‐Rossi, 2016, BJU international.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).

A. Ravaud, S. Culine, B. Escudier, 2015 .

Sorafenib in advanced clear-cell renal-cell carcinoma.

Apurva A Desai, Walter M Stadler, Scott Freeman, 2007, The New England journal of medicine.

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Jacques Bernier, Michel Bolla, Mahmut Ozsahin, 2004, The New England journal of medicine.

Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France.

G. Calais, E. Baudin, E. Babin, 2019, European journal of cancer.

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

M. Rimbert, I. Philip, E. Bompas, 2008, Cancer Immunology, Immunotherapy.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

A. Schueler, R. Knecht, R. Hitt, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

C. Borel, J. Thariat, C. Sire, 2021, Annals of Oncology.

An international phase 3 trial in head and neck cancer: Quality of life and symptom results

I. Barillot, A. Bottomley, C. Coens, 2014, Cancer.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

A. Ravaud, T. Powles, J. Carles, 2021, Nature Medicine.

Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

N. Magné, B. Chauffert, F. Clatot, 2023, European journal of cancer.

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

N. Magné, B. Chauffert, J. Bourhis, 2020, The Lancet. Oncology.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Apurva A Desai, Walter M Stadler, M. Gore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

A. Ravaud, S. Culine, G. Deplanque, 2015, The Lancet. Oncology.

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study

S. Oudard, P. Barthélémy, C. Vicier, 2022, Cancers.

Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemoradiotherapy in resectable hypopharynx and larynx cancers. EORTC protocol 24954–22950

J. Horiot, D. Lacombe, J. Bogaerts, 2007 .

Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.

J. Horiot, R. Stupp, D. Lacombe, 2009, Journal of the National Cancer Institute.

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

Frank Pétavy, Jean-Pascal Machiels, Patrick Schöffski, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

N. Rioux-Leclercq, A. Ravaud, B. Escudier, 2020, European journal of cancer.

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).

N. Rioux-Leclercq, F. Goldwasser, B. Escudier, 2021, European journal of cancer.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

L. Collette, S. Fosså, P. Albers, 2015, The Lancet. Oncology.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

A. Ravaud, J. Machiels, B. Esterni, 2013, The Lancet. Oncology.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

A. Ravaud, S. Culine, G. Deplanque, 2012, European journal of cancer.

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.

A. Ravaud, S. Culine, G. Le Teuff, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

844 A phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder

S. Culine, B. Bui, N. James, 2003 .

Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.

S. Culine, B. Duclos, B. Escudier, 2007, The Journal of urology.

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study

R. Motzer, T. Choueiri, J. McCaffrey, 2021, Acta oncologica.

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

K. Bensalah, A. Ravaud, J. Bernhard, 2021, European urology.

CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.

K. Bensalah, A. Ravaud, C. Beisland, 2018, Journal of Clinical Oncology.

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.

C. Porta, R. Motzer, T. Powles, 2021 .

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

R. Motzer, T. Powles, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.

K. Bensalah, A. Ravaud, H. Lang, 2019, Journal of Clinical Oncology.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

T. Powles, G. De Velasco, P. Kellokumpu-Lehtinen, 2019, European journal of cancer.

Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.

B. Escudier, S. Oudard, G. Gravis, 2020 .

Bilateral breast metastases from ewing sarcoma of the femur.

M. Lacroix-Triki, L. Astudillo, C. Chevreau, 2005, American journal of clinical oncology.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.

F. Caponigro, X. Pivot, A. Awada, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

M. Rimbert, H. Bruzzoni-Giovanelli, F. Calvo, 2010, Cancer Immunology, Immunotherapy.

Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.

P. Fumoleau, M. Giovannini, F. Rolland, 1997, Oral oncology.

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2009, Investigational New Drugs.

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

Caen, T. Conroy, M. Barberi-Heyob, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M. van Glabbeke, J. Armand, P. Fumoleau, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

S. Culine, B. Bui, N. James, 2006, British Journal of Cancer.

[Efficacy of pneumatic retinopexy: 7 year retrospective study].

F. Rolland, A. Gribomont, 1996, Bulletin de la Societe belge d'ophtalmologie.

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

R. Bukowski, C. Szczylik, Thomas E. Hutson, 2007 .

Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer

C. Pfister, P. Eschwege, B. Albouy, 2007, BJU international.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

S. Culine, C. Logothetis, G. Gravis, 2014, The Lancet. Oncology.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study.

J. Baselga, R. Knecht, R. Hitt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

I. Bièche, S. Chevret, J. Grob, 2020 .

Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.

B. Escudier, S. Oudard, G. Gravis, 2019, Journal of Clinical Oncology.

Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study.

S. Culine, J. Droz, F. Joly, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.

G. Deplanque, S. Oudard, G. Gravis, 2015 .

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

S. Culine, G. Gravis, Anne-Laure Martin, 2014 .

Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status.

S. Culine, S. Oudard, P. Beuzeboc, 2013 .

Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.

J. Bourhis, E. Babin, P. Maingon, 2017 .

1050PDThe ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit

E. Blot, C. Sire, X. Sun, 2017 .

Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

S. Culine, D. Drubay, G. Deplanque, 2023, Clinical Genitourinary Cancer.

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).

Y. Allory, S. Oudard, G. Gravis, 2023, European journal of cancer.

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Y. Allory, S. Oudard, G. Gravis, 2020 .

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

S. Oudard, M. Baciuchka, M. Laramas, 2016, European journal of cancer.

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

J. Klijanienko, I. Bièche, M. Kamal, 2021, Investigational New Drugs.

PREDICTOR (UNICANCER GEP11): Randomized phase II study of preoperative afatinib in untreated head and neck squamous cell carcinoma (HNSCC) patients.

J. Klijanienko, I. Bièche, G. Dolivet, 2017 .

A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.

M. Campone, A. Stenzl, N. de Bont, 2013, The oncologist.

Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.

C. Porta, T. Powles, R. Motzer, 2023, European urology oncology.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS

C. Terret, L. Campion, F. Priou, 2023, Journal of clinical medicine.

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

C. Borel, V. Costes, D. Cupissol, 2019, Journal of Clinical Oncology.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

S. Culine, J. Bernhard, J. Larkin, 2017, European journal of cancer.

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.

S. Culine, J. Droz, B. Escudier, 2002, The Journal of urology.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

T. Powles, G. De Velasco, P. Kellokumpu-Lehtinen, 2019, European journal of cancer.

Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC).

A. Ravaud, H. von der Maase, N. Zantl, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.

S. Culine, B. Escudier, S. Oudard, 2021, European urology.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004–02

N. Daly-Schveitzer, Y. Tao, E. Bompas, 2013, Radiation Oncology.

Survival outcomes, prognostic factors, and effect of adjuvant radiotherapy and prophylactic neck dissection in salivary acinic cell carcinoma: A prospective multicenter REFCOR study of 187 patients.

G. Calais, F. Clatot, E. Babin, 2023, European journal of cancer.

Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results.

T. Conroy, M. Barberi-Heyob, J. Merlin, 1994, Anticancer research.

63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies

J. Limacher, O. Lantz, O. Capitain, 2020 .

Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.

G. Gravis, S. Chabaud, C. Chevreau, 2017 .

Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

T. Powles, R. Motzer, T. Choueiri, 2016 .

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study

R. Motzer, M. Voss, V. Grünwald, 2022, European Urology Open Science.

PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).

F. Bidault, C. Borel, V. Costes, 2016 .

Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study

J. Bourhis, F. Clatot, C. Sire, 2019, Annals of Oncology.

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

M. van Glabbeke, J. Bourhis, M. Bolla, 2004, The New England journal of medicine.

Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON).

M. Campone, F. Joly, A. Stenzl, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

T. Powles, S. Park, J. Bellmunt, 2021 .

A phase II prospective study of gemcitabine and platin-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study

S. Culine, B. Duclos, S. Oudard, 2005 .

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity

S. Vacher, E. Girard, M. Kamal, 2023, Scientific reports.

An international phase 3 trial in head and neck cancer: Quality of life and symptom results

I. Barillot, A. Bottomley, C. Coens, 2014, Cancer.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis.

G. Gravis, F. Joly, P. Barthélémy, 2020 .